Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing a new antibody called PRL3-zumab to treat wet age-related macular degeneration (a progressive eye condition that damages central vision). Researchers want to see if this drug is safe and whether it can help preserve or improve vision in people whose eyes haven't responded well to standard treatments.
Wet macular degeneration can keep getting worse even with current standard treatments. This trial is exploring a new drug that works differently—by targeting a protein involved in abnormal blood vessel growth in the eye—to help patients who have already tried at least two standard treatments without enough benefit.
You likely qualify if…
You likely don't qualify if…
You would receive three injections into your eye over the first 4 weeks, spaced 2 weeks apart. You would then be monitored for 20 additional weeks with visits every 4 weeks to check your vision, examine the back of your eye with imaging, and monitor for any side effects. The entire trial lasts 24 weeks (about 6 months), and you'll have blood tests and general health checks throughout.
AI-generated summary from trial data · Apr 30, 2026 · Not medical advice
Singapore